Menopausal hormone therapy (MHT) in premature ovarian insufficiency (POI): Principles and recommendations
| Systemic MHT is physiologic estrogen replacement in women with POI; oral or transdermal MHT that achieves estrogen replacement levels is recommended as a first-line approach |
| MHT is indicated to reduce long-term health risks associated with POI and to treat symptoms of estrogen deficiency |
| MHT is indicated until age 50 to 51 even if estrogen-deficiency symptoms are absent |
| The need to continue MHT beyond age 50 to 51 should be based on a personalized risk-benefit assessment |
| Systemic MHT does not provide contraception in women with POI |
| Women’s Health Initiative study results should not be extrapolated to treatment decision-making in women with POI or early menopause because these individuals were not included in the study22 |
Based on information from references 1, 5, and 19.